Gainers
-
Longfin Corp. (NASDAQ: LFIN) shares surged 47.3
percent to close at $28.189 on Friday after climbing 64.86 percent on Thursday.
-
Genprex, Inc. (NASDAQ: GNPX) jumped 31.74 percent
to close at $5.45 on Friday.
-
Broadwind Energy, Inc. (NASDAQ: BWEN) shares
gained 28.94 percent to close at $3.03 after the company disclosed that it has recently booked $10 million in new tower orders
and Gearing segment orders of $15 million in Q1.
-
Marrone Bio Innovations, Inc. (NASDAQ: MBII)
shares jumped 21.72 percent to close at $3.25.
-
NuCana plc (NASDAQ: NCNA) shares gained 16.94
percent to close at $26.23.
-
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) shares
rose 13.98 percent to close at $7.01 on Friday.
-
FTD Companies, Inc. (NYSE: FTD) shares climbed 13.33
percent to close at $5.10.
-
GOL Linhas Aéreas Inteligentes S.A. (NYSE: GOL)
shares gained 12.97 percent to close at $14.11 on Friday. Bank of America upgraded Gol Linhas from Neutral to Buy.
-
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX)
shares rose 12.88 percent to close at $33.30. Pacira reported the FDA approval of supplemental new drug application for
EXPAREL.
-
Radiant Logistics, Inc. (NASDAQ: RLGT) gained
10.08 percent to close at $4.04.
-
Freshpet, Inc. (NASDAQ: FRPT) shares rose 10.06
percent to close at $18.05 on Friday.
-
BIO-key International, Inc. (NASDAQ: BKYI) shares
gained 9.59 percent to close at $2.40.
-
NII Holdings, Inc. (NASDAQ: NIHD) shares climbed
6.61 percent to close at $2.42.
-
PriceSmart, Inc. (NASDAQ: PSMT) gained 5.5
percent to close at $88.225 after the company reported stronger-than-expected results for its second quarter on Thursday.
Losers
-
NewLink Genetics Corporation (NASDAQ: NLNK)
shares tumbled 42.62 percent to close at $4.20 on Friday.
-
MannKind Corporation (NASDAQ: MNKD) fell 24.79
percent to close at $1.79. MannKind priced its 14 million share registered direct offering at $2 per share.
-
Incyte Corporation (NASDAQ: INCY) declined 22.93
percent to close at $64.02 after the company , announced Friday a disappointing update to a phase 3 trial. Incyte said its
experimental therapy called epacadostat failed in a phase 3 trial called ECHO-301 to improve the efficacy of Merck & Co's
Keytruda when the two therapies were combined to treat patients suffering from melanoma.
-
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA)
shares dipped 19.5 percent to close at $12.67.
-
Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT)
tumbled 19.21 percent to close at $27.68.
-
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX)
shares fell 18.74 percent to close at $10.84.
-
Boston Omaha Corporation (NASDAQ: BOMN) shares
dipped 17.86 percent to close at $22.40.
-
Net Element, Inc. (NASDAQ: NETE) shares fell
17.36 percent to close at $7.33 on Friday after jumping 32.98 percent on Thursday.
-
Luna Innovations Incorporated (NASDAQ: LUNA)
shares dropped 15.92 percent to close at $3.17.
-
Finjan Holdings, Inc. (NASDAQ: FNJN) fell 15.68
percent to close at $2.85.
-
Northern Oil and Gas, Inc. (NYSE: NOG) dipped 14.45
percent to close at $1.48. Northern Oil and Gas priced 58.67 million shares at $1.50 per share.
-
Sunrun Inc. (NASDAQ: RUN) shares fell 14.29
percent to close at $8.52. Bank of America downgraded Sunrun from Buy to Underperform.
-
resTORbio, Inc. (NASDAQ: TORC) fell 11.29 percent
to close at $8.49.
-
Iteris, Inc. (NASDAQ: ITI) shares fell 9.46
percent to close at $4.50 on Friday.
-
New Media Investment Group Inc. (NYSE: NEWM) fell
6.38 percent to close at $16.30. New Media Investment Group priced its 6 million share offering at $16.5 per share.
-
ORBCOMM Inc (NASDAQ: ORBC) fell 4.01 percent to
close at $8.85. ORBCOMM priced its 3 million share common stock offering at $8.60 per share.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.